These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8805030)

  • 21. Therapeutic implications of diabetes in cardiovascular disease.
    Cherian B; Meka N; Katragadda S; Arora R
    Am J Ther; 2009; 16(6):e51-9. PubMed ID: 19940606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin immunotherapy for pretype 1 diabetes.
    Jacobsen LM; Schatz DA
    Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):390-396. PubMed ID: 34091488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Problems of the prevention and treatment of pancreatic diabetes mellitus].
    Genes SG
    Klin Med (Mosk); 1978 Jul; 56(7):87-95. PubMed ID: 355722
    [No Abstract]   [Full Text] [Related]  

  • 24. Prediabetes Screening and Treatment in Diabetes Prevention: The Impact of Physician Attitudes.
    Mainous AG; Tanner RJ; Scuderi CB; Porter M; Carek PJ
    J Am Board Fam Med; 2016 Nov; 29(6):663-671. PubMed ID: 28076248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sulfonylureas, diabetes and prediabetes].
    Leocadio J
    Prensa Med Argent; 1966; 53(1):633-5. PubMed ID: 5986291
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug therapy in prediabetes.
    Mukhopadhyay P; Chowdhury S
    J Indian Med Assoc; 2005 Nov; 103(11):603-5, 608. PubMed ID: 16570765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyherbal dietary supplementation for prediabetic adults: study protocol for a randomized controlled trial.
    Feinberg T; Wieland LS; Miller LE; Munir K; Pollin TI; Shuldiner AR; Amoils S; Gallagher L; Bahr-Robertson M; D'Adamo CR
    Trials; 2019 Jan; 20(1):24. PubMed ID: 30616613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic treatment options for prediabetes.
    Hsueh WA; Handelsman Y
    Nat Clin Pract Endocrinol Metab; 2008 Jul; 4(7):380-1. PubMed ID: 18523427
    [No Abstract]   [Full Text] [Related]  

  • 29. Rationale, Design, and Baseline Characteristics of Beijing Prediabetes Reversion Program: A Randomized Controlled Clinical Trial to Evaluate the Efficacy of Lifestyle Intervention and/or Pioglitazone in Reversion to Normal Glucose Tolerance in Prediabetes.
    Luo Y; Paul SK; Zhou X; Chang C; Chen W; Guo X; Yang J; Ji L; Wang H
    J Diabetes Res; 2017; 2017():7602408. PubMed ID: 28168204
    [No Abstract]   [Full Text] [Related]  

  • 30. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zinc supplementation for improving glucose handling in pre-diabetes: A double blind randomized placebo controlled pilot study.
    Islam MR; Attia J; Ali L; McEvoy M; Selim S; Sibbritt D; Akhter A; Akter S; Peel R; Faruque O; Mona T; Lona H; Milton AH
    Diabetes Res Clin Pract; 2016 May; 115():39-46. PubMed ID: 27242121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediabetes and macrovascular disease: Review of the association, influence on outcome and effect of treatment.
    Kleinherenbrink W; Osei E; den Hertog HM; Zandbergen AAM
    Eur J Intern Med; 2018 Sep; 55():6-11. PubMed ID: 30007840
    [No Abstract]   [Full Text] [Related]  

  • 34. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
    Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
    Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin for prediabetes.
    Med Lett Drugs Ther; 2016 Nov; 58(1507):141. PubMed ID: 27805573
    [No Abstract]   [Full Text] [Related]  

  • 38. Metformin Prescription for Insured Adults With Prediabetes From 2010 to 2012.
    Rodriguez-Gutierrez R; Montori VM
    Ann Intern Med; 2015 Sep; 163(6):482-3. PubMed ID: 26370016
    [No Abstract]   [Full Text] [Related]  

  • 39. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review.
    Pu MZ; Christensen-Adad FC; Gonçalves AC; Minicucci WJ; Ribeiro JD; Ribeiro AF
    Rev Paul Pediatr; 2016 Sep; 34(3):367-73. PubMed ID: 26994743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.